Abstract | BACKGROUND: METHODS: This study is a retrospective review of all consecutive patients with Coats disease treated with neoadjuvant or adjuvant intravitreal ranibizumab plus conventional and amblyopia treatment as appropriate. RESULTS: Nine patients (median age, 13 months) presenting Coats Stages 3B and 4 (5 and 4 eyes, respectively) were included. Iris neovascularization resolved within 2 weeks and retinal reapplication within 4 months in all patients. At last follow-up, globe survival was 100% with anatomical success in 8 of the 9 eyes. With a median follow-up of 50 months, fibrotic vitreoretinopathy was developed in 5 of the 9 cases, one leading to tractional retinal detachment and ultimately phthisis bulbi. The remaining 4 of the 9 eyes achieved some vision (range, 0.02-0.063). CONCLUSION: To the best of the authors' knowledge, this is the largest reported series of late-stage Coats undergoing anti- vascular endothelial growth factor therapy, a homogenous cohort of patients treated with a single agent and with the longest follow-up. This study supports the role of ranibizumab in advanced disease by transient restoration of the hemato- retinal barrier and suppression of neovascularization to facilitate classic treatment. At the last follow-up, the authors report unprecedented anatomical success and functional outcome.
|
Authors | Marie-Claire Gaillard, Assimina Mataftsi, Aubin Balmer, Susan Houghton, Francis L Munier |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 34
Issue 11
Pg. 2275-81
(Nov 2014)
ISSN: 1539-2864 [Electronic] United States |
PMID | 25075562
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Ranibizumab
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Chemotherapy, Adjuvant
- Child, Preschool
- Female
- Follow-Up Studies
- Humans
- Infant
- Intravitreal Injections
- Male
- Ranibizumab
- Retinal Detachment
(drug therapy, etiology)
- Retinal Telangiectasis
(drug therapy)
- Retrospective Studies
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
|